@article{fdi:010079267,
  title = {{S}tatin therapy is associated with lower prevalence of gut microbiota dysbiosis [plus {M}ethods, {E}xtended data figures, {S}upplementary information, and {N}ature {R}esearch reporting summary]},
  author = {{V}ieira-{S}ilva, {S}. and {F}alony, {G}. and {B}elda, {E}. and {N}ielsen, {T}. and {A}ron-{W}isnewsky, {J}. and {C}hakaroun, {R}. and {F}orslund, {S}.{F}. and {A}ssmann, {K}. and {V}alles-{C}olomer, {M}. and {N}guyen, {T}.{T}.{D}. and {P}roost, {S}. and {P}rifti, {E}di and {T}remaroli, {V}. and {P}ons, {N}. and {L}e {C}hatelier, {E}. and {A}ndreelli, {F}. and {B}astard, {J}.{P}. and {C}oelho, {L}.{P}. and {G}alleron, {N}. and {H}ansen, {T}.{H}. and {H}ulot, {J}.{S}. and {L}ewinter, {C}. and {P}edersen, {H}.{K}. and {Q}uinquis, {B}. and {R}ouault, {C}. and {R}oume, {H}. and {S}alem, {J}.{E}. and {S}øndertoft, {N}.{B}. and {T}ouch, {S}. and {D}umas, {M}.{E}. and {E}hrlich, {S}.{D}. and {G}alan, {P}. and {G}øtze, {J}.{P}. and {H}ansen, {T}. and {H}olst, {J}.{S}. and {K}øber, {L}. and {L}etunic, {I}. and {N}ielsen, {J}. and {O}ppert, {J}.{M}. and {S}tumvoll, {M}. and {V}estergaard, {H}. and {Z}ucker, {J}ean-{D}aniel and {B}ork, {P}. and {P}edersen, {O}. and {B}äckhed, {F}. and {C}l{\'e}ment, {K}. and {R}aes, {J}. and {M}etacardis {C}onsortium},
  editor = {},
  language = {{ENG}},
  abstract = {{M}icrobiome community typing analyses have recently identified the {B}acteroides2 ({B}act2) enterotype, an intestinal microbiota configuration that is associated with systemic inflammation and has a high prevalence in loose stools in humans. {B}act2 is characterized by a high proportion of {B}acteroides, a low proportion of {F}aecalibacterium and low microbial cell densities and its prevalence varies from 13% in a general population cohort to as high as 78% in patients with inflammatory bowel disease. {R}eported changes in stool consistency and inflammation status during the progression towards obesity and metabolic comorbidities led us to propose that these developments might similarly correlate with an increased prevalence of the potentially dysbiotic {B}act2 enterotype. {H}ere, by exploring obesity-associated microbiota alterations in the quantitative faecal metagenomes of the cross-sectional {M}eta{C}ardis {B}ody {M}ass {I}ndex {S}pectrum cohort (n = 888), we identify statin therapy as a key covariate of microbiome diversification. {B}y focusing on a subcohort of participants that are not medicated with statins, we find that the prevalence of {B}act2 correlates with body mass index, increasing from 3.90% in lean or overweight participants to 17.73% in obese participants. {S}ystemic inflammation levels in {B}act2-enterotyped individuals are higher than predicted on the basis of their obesity status, indicative of {B}act2 as a dysbiotic microbiome constellation. {W}e also observe that obesity-associated microbiota dysbiosis is negatively associated with statin treatment, resulting in a lower {B}act2 prevalence of 5.88% in statin-medicated obese participants. {T}his finding is validated in both the accompanying {M}eta{C}ardis cardiovascular disease dataset (n = 282) and the independent {F}lemish {G}ut {F}lora {P}roject population cohort (n = 2,345). {T}he potential benefits of statins in this context will require further evaluation in a prospective clinical trial to ascertain whether the effect is reproducible in a randomized population and before considering their application as microbiota-modulating therapeutics.},
  keywords = {},
  booktitle = {},
  journal = {{N}ature},
  volume = {581},
  numero = {},
  pages = {310--315 [+ 21 ]},
  ISSN = {0028-0836},
  year = {2020},
  DOI = {10.1038/s41586-020-2269-x},
  URL = {https://www.documentation.ird.fr/hor/fdi:010079267},
}